CriticalCentrally-acting antiadrenergic agent×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)
Updated · Methodology
Mechanism
Phenelzine is a potent monoamine oxidase (MAO) inhibitor (phenelzine label, US Food and Drug Administration, FDA, Description). According to its label, MAO inhibitors potentiate sympathomimetic substances and related compounds, methyldopa among them, and this may result in hypertensive crises (FDA phenelzine label, Contraindications). Methyldopa probably lowers blood pressure through its metabolite alpha-methylnoradrenaline. This metabolite stimulates central inhibitory alpha-adrenergic receptors, acts as a false neurotransmitter and/or reduces plasma renin activity. Methyldopa also lowers tissue concentrations of serotonin, dopamine, noradrenaline and adrenaline (methyldopa summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). The Spanish methyldopa SmPC states that MAO inhibitors may reduce the antihypertensive effect of methyldopa (methyldopa SmPC, AEMPS, section 4.5).
Symptoms
The main risk of the combination is a hypertensive crisis (phenelzine label, US Food and Drug Administration, FDA, Contraindications). A hypertensive crisis with phenelzine presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea, vomiting, sweating (sometimes with fever and sometimes with cold, clammy skin), dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding has occurred with the rise in blood pressure, and some crises have been fatal (FDA phenelzine label, Warnings). The documents also describe other blood pressure changes: with antihypertensive drugs, phenelzine may cause an exaggerated fall in blood pressure (FDA phenelzine label, Warnings). The Spanish methyldopa summary of product characteristics (SmPC), on the other hand, states that monoamine oxidase inhibitors may reduce the antihypertensive effect of methyldopa (methyldopa SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5).
Management
The combination is contraindicated. The Spanish methyldopa summary of product characteristics (SmPC) contraindicates methyldopa during treatment with monoamine oxidase (MAO) inhibitors (methyldopa SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3), and the US methyldopa label also contraindicates it in patients on MAO inhibitors (methyldopa label, US Food and Drug Administration, FDA, Contraindications). The US phenelzine label lists methyldopa among the compounds that patients treated with phenelzine should not take (FDA phenelzine label, Contraindications). The Spanish methyldopa SmPC also contraindicates methyldopa in depression (methyldopa SmPC, AEMPS, section 4.3), and phenelzine is used for depression (FDA phenelzine label, Indications). Phenelzine is not authorised in Spain (AEMPS medicines register), so information on it comes from the US label. None of these documents gives an interval between stopping phenelzine and starting methyldopa. With phenelzine, check blood pressure often and stop phenelzine at once if palpitations or frequent headaches appear (FDA phenelzine label, Warnings). In a hypertensive crisis, stop phenelzine and start lowering blood pressure immediately: the US phenelzine label recommends phentolamine (a reported dose of 5 mg intravenously), given slowly to avoid an excessive fall in blood pressure. Manage fever during the crisis with external cooling (FDA phenelzine label, Warnings).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Metildopa, Aldomet Forte 500 mg (nº registro 53587), sección 4.3 (2024)– AEMPS, CIMA, nº registro 53587 (Aldomet Forte 500 mg comprimidos recubiertos con película, H.A.C. Pharma; ficha común con Aldomet 250 mg), revisión 02/2024 (texto revisado 06/2018), secciones 4.3, 4.5, 4.8 y 5.1
- FDA: Methyldopa tablets (Rising Pharma) prescribing information (2025)– FDA, DailyMed setid 9e22e1d8-04ec-4b67-92ea-b09c706f2703 (Rising Pharma Holdings), versión 3, revisión 03/2025, Contraindications, Clinical Pharmacology y Precautions